8-K: 89bio Stockholders Re-Elect Directors, Approve Auditor and Executive Compensation at Annual Meeting

89bio, Inc. announced that all director nominees were elected and all proposals, including the ratification of KPMG LLP as independent auditor and the advisory vote on executive compensation, were approved at its 2025 Annual Meeting of Stockholders.

Summary

• 89bio, Inc. held its 2025 Annual Meeting of Stockholders on Wednesday, May 28, 2025, at 9:00 a.m. Pacific Time.
• As of the record date of April 3, 2025, there were 145,984,182 shares of common stock entitled to vote at the meeting.
• All director nominees for Class III Directors were elected: Martin Babler (104,787,288 votes For), Derek DiRocco, Ph.D. (63,538,191 votes For), and Lota Zoth, C.P.A. (121,166,878 votes For).
• Proposal 2, the ratification of KPMG LLP as the independent auditor, was approved with 134,065,959 votes For.
• Proposal 3, the advisory vote on executive compensation, was approved with 114,892,045 votes For.

Sentiment

Score: 7

Explanation: The successful approval of all proposals and election of all director nominees indicates stable corporate governance, though a notable portion of shareholders withheld votes for one director, introducing a slight nuance.

Positives

• All director nominees were successfully elected, ensuring continuity of the board's Class III members.
• The ratification of KPMG LLP as the independent auditor was approved by a significant majority, confirming the company's chosen independent auditor.
• The advisory vote on executive compensation was approved, indicating shareholder support for current executive pay practices.

Negatives

• Derek DiRocco, Ph.D. received a substantial number of 'Votes Withheld' (61,123,923) compared to 'Votes For' (63,538,191) for his election as a Class III Director, indicating a notable portion of shareholders did not support his re-election, despite him being elected.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 89bio, Inc. Date: May 30, 2025 By: /s/ Rohan Palekar Rohan Palekar Chief Executive Officer"

Industry Context

Routine annual meetings are standard for publicly traded companies across all industries, including biotechnology. The approval of directors, auditors, and executive compensation are typical agenda items, reflecting standard corporate governance practices.

Comparison to Industry Standards

• The successful election of all directors and approval of key proposals is a standard outcome for well-governed companies in the biotechnology sector and broader market.
• The relatively high 'withheld' votes for Derek DiRocco, Ph.D. (61,123,923 votes withheld vs. 63,538,191 votes for) for an uncontested director election is notable and could be higher than typical industry averages for such votes, suggesting a degree of shareholder dissent or concern regarding this specific director.

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes were counted, and the company's governance structure remains consistent with the re-election of directors and approval of key proposals, reflecting shareholder participation in corporate decisions.
• Management: Executive compensation practices received advisory approval, providing validation for the current compensation framework.
• Auditors: KPMG LLP's role as independent auditor was ratified, confirming their continued engagement for financial audits.

Key Dates

Recommendation

Keywords

89bio, ETNB, Annual Meeting, Stockholders, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, 8-K, Biotechnology